Hwasun Chonnam National University Hospital Partners with Global Clinical Trial Specialists for Clinical Research Collaboration

(From left) Daniel Kim, Director of Acrostar, Sanghee Cho, Director of Clinical Trial Center at Hwasun Chonnam National University Hospital, and Hyunkyung Kim, Head of Novotech Asia Korea, are signing the business agreement and taking a commemorative photo. Provided by Hwasun Chonnam National University Hospital

Hwasun Chonnam National University Hospital announced on August 25 that it has signed a memorandum of understanding (MOU) for "clinical research activation" with Novotech Asia Korea, a global clinical trial specialist, and Acrostar, a company specializing in on-site management services.

The signing ceremony, held on August 21 at the Kim Jaebong Hall on the first floor of the hospital's Future Medical Innovation Center, was attended by Sanghee Cho, Director of the Clinical Trial Center at Hwasun Chonnam National University Hospital, Jaesook Ahn, Vice Director of Research, and Suwoong Yoo, Head of Research Planning. Also present were Hyunkyung Kim, Head of Novotech Asia Korea, along with executives, and Daniel Kim, Director of Acrostar.

Through this agreement, Novotech Asia Korea will expand opportunities for collaboration with the hospital's researchers, while Acrostar will support the on-site operation of clinical trials. Hwasun Chonnam National University Hospital plans to focus on increasing researcher participation to enhance the quality of clinical trials.

This agreement is expected to create synergies, as it is linked to the hospital's recent selection as the lead institution for the "Digital Bio Smart Clinical Support Platform Construction Project," which has a total budget of 17.6 billion KRW (approximately 13 million USD).

This project, known as the "K-HOPE Project," aims to develop personalized treatment methods for patients by integrating artificial intelligence (AI) and digital technologies, as well as to improve the speed and reliability of clinical trials. The combination of global clinical partnerships and a foundation of digital innovation is expected to further strengthen efforts to solve the challenges of new drug development.

After the signing ceremony, a briefing session was held on the topic of "Early Clinical Trials and Regulatory Strategies Based on New Technologies." Novotech Asia Korea shared insights on changes in the global clinical trial environment, strategies for early-stage clinical trials, and regulatory processes, and discussed ways to collaborate with the hospital's researchers and local bio companies.

Hwasun Chonnam National University Hospital is recognized as a cancer-specialized hospital not only in Korea but also globally. It is located at the core of the Hwasun Vaccine Special Zone and the National Advanced Strategic Industry Bio-Specialized Complex in Hwasun, Jeonnam. With a large patient pool and extensive clinical experience, the hospital is considered well-positioned to accelerate the clinical trial phase, which is the most challenging stage of new drug development.

Sanghee Cho, Director of the Clinical Trial Center at Hwasun Chonnam National University Hospital, stated, "This agreement will serve as an opportunity to substantially expand the hospital's clinical capabilities in partnership with global collaborators. We will create an environment where researchers can participate more actively, thereby accelerating the development of new drugs."

Min Jungjun, President of Hwasun Chonnam National University Hospital, said, "Through this agreement, we expect to further enhance the status of the Hwasun Vaccine Special Zone, which is growing as an advanced biohealth cluster focused on vaccines, anticancer, and immunology. We also anticipate that our hospital will strengthen its global competitiveness in the field of clinical trials, which is a major challenge in new drug development."

This content was produced with the assistance of AI translation services.